Jon Halbert, serving as a director at Caris Life Sciences, Inc. (NASDAQ: CAI), has executed a substantial insider purchase, acquiring 68,000 shares of the company's common stock on May 15, 2026. The transaction, valued at $990,080, was facilitated through LAH Investments, Ltd., and reflects a weighted average purchase price of $14.56 per share. This acquisition occurs against a backdrop of Caris Life Sciences' recent financial performance and strategic market expansions, including the launch of its Caris Detect early cancer detection screening service and a newly authorized $100 million share repurchase program.
The transaction details indicate that the shares were acquired at prices ranging from $14.49 to $14.60 per share. Following this acquisition, LAH Investments, Ltd. holds a total of 704,598 shares, which includes an aggregate of 11,598 shares received in pro rata distributions. The reporting person has disclaimed beneficial ownership of these shares except to the extent of his pecuniary interest therein. Halbert also directly holds 118,621 shares of Caris Life Sciences common stock. Additionally, an indirect holding of 637,887 shares is maintained through a Family Trust, which includes an aggregate of 23,196 shares received in pro rata distributions.
Caris Life Sciences recently reported significant financial results for the first quarter of 2026, with total revenue reaching $216 million, reflecting a 79% increase compared to the previous year. The company's earnings per share (EPS) exceeded expectations, coming in at $0 against the forecasted loss of $0.12. Additionally, Caris Life Sciences announced a $100 million share buyback program authorized by its Board of Directors, allowing for repurchases through various means, including open market purchases.
Furthermore, the company launched Caris Detect, entering the early cancer detection screening market, a move that was met with a Buy rating and a $32.00 price target from BTIG analyst Mark Massaro. Caris also expanded its market presence with a dual listing on NYSE Texas, aiming to increase investor exposure. In another development, Caris Life Sciences identified 13,293 patients eligible for new cancer therapies through its Lookback Program, analyzing FDA approvals across multiple tumor types.
According to InvestingPro analysis, Caris Life Sciences appears undervalued, with a Fair Value of $18.59, placing it among stocks on the Most Undervalued list. The company holds a "GREAT" financial health score of 3.08 out of 5. The stock currently trades at $16.99, representing a gain on Halbert's purchase.